Related Experiment Video

Updated: May 21, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Stroke prevention in atrial fibrillation: current status and emerging therapies

Walter Van Mieghem1, Georges Mairesse, Luc Missault

  • 1Dept. of Cardiology, Ziekenhuis Oost Limburg, Belgium. walter.vanmieghem@zol.be

Acta Cardiologica
|May 31, 2012
PubMed

Insights

Atrial fibrillation (AF) significantly increases stroke risk. Despite guidelines, many AF patients undertreat this risk due to underdiagnosis and limitations of vitamin K antagonists, necessitating improved awareness and novel anticoagulants.

Area of Science:

  • Cardiology
  • Neurology
  • Public Health

Background:

  • Stroke is a leading cause of death and disability, with Atrial Fibrillation (AF) being a major modifiable risk factor.
  • AF increases stroke risk fivefold, but risk stratification and treatment remain suboptimal in many patients.
  • Current guidelines recommend antithrombotic therapy, primarily vitamin K antagonists (VKA), for stroke prevention in AF.

Purpose of the Study:

  • To highlight the significant stroke risk associated with Atrial Fibrillation (AF).
  • To identify barriers to adequate thromboprophylaxis in AF patients.
  • To advocate for improved AF diagnosis and explore alternative anticoagulant therapies.

Main Methods:

  • Review of existing literature on stroke, Atrial Fibrillation, and thromboprophylaxis.
  • Analysis of factors contributing to underutilization of anticoagulants.
  • Discussion of current risk assessment scores and treatment guidelines.

Main Results:

  • Atrial Fibrillation is a prevalent arrhythmia significantly elevating stroke risk.
  • Underdiagnosis of AF and underuse of VKAs are common due to various patient and physician factors.
  • Limitations of VKAs, including drug interactions and monitoring requirements, hinder optimal use.

Conclusions:

  • Increased awareness campaigns for AF diagnosis are crucial for stroke prevention.
  • Novel oral anticoagulants offer promising alternatives to VKAs, potentially improving patient outcomes.
  • Addressing barriers to anticoagulation is essential for reducing stroke burden in AF patients.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...